The advantage of our prediction model was that we used HER2/CEP17 ratio and histological grade as two factors because they were recognized factors that were associated with pCR in HER2-positive breast cancer, and we also added CD8+TILs immune factor as one of the indicators. This evidence concerns the gene ERBB2 and breast carcinoma.